[June 13, 2016] |
|
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® lid and lash hygiene for the domestic eye care
market, announces the appointment of Mark M. Sieczkarek as President and
Chief Executive Officer, effectively immediately. Sieczkarek has been a
NovaBay Director since January 2014, was named Chairman in April 2015
and has served as interim President and CEO since November 2015. He has
been instrumental in the development and implementation of the
go-to-market strategy for Avenova.
"I'm delighted to take on the executive responsibilities on a permanent
basis and am fully committed to the successful commercialization of
Avenova," said Sieczkarek. "I'm proud of our team's many fast-paced
activities to advance the marketing strategy and appreciate the support
from our Board in pursuing our goals. With our new strategy now in
place, expense management in hand, a strengthened balance sheet and
long-term committed investors, we are on track to achieve our target of
positive cash flow from operations by the end of 2016 and accelerated
revenue growth beyond."
Mr. Sieczkarek previously was CEO of Solta Medical, Inc. (acquired by
Valeant Pharmaceuticals) and of Conceptus, Inc. (acquired by Bayer
HealthCare), where he led the launch of the medical device Essure®.
Prior to that, he was Senior Vice President and President of The
Americas and Europe for the leading ophthalmic company Bausch & Lomb
(acquired by Valeant Pharmaceuticals), where he was responsible for
overseeing multinational commercial launches of several leading products.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the
commercialization of prescription Avenova® lid and lash
hygiene for the eye care market. Avenova is formulated with Neutrox™,
which is cleared by the U.S. Food and Drug Administration (FDA) as a
510(k) medical device. Neutrox is NovaBay's pure hypochlorous acid.
Laboratory tests show that pure hypochlorous acid has potent
antimicrobial activity in solution yet is non-toxic to mammalian cells
and it also neutralizes bacterial toxins. Data from a multicenter
clinical study show that Avenova reduced bacterial load, the underlying
cause of blepharitis, on ocular skin surface by more than 90%. Avenova
is marketed to optmetrists and ophthalmologists throughout the U.S. by
NovaBay's direct medical salesforce. It is accessible from more than 90%
of retail pharmacies in the U.S. through agreements with McKesson
Corporation, Cardinal Health and AmeriSource Bergen.
Forward-Looking Statements
This release contains forward-looking statements, which are based
upon management's current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not limited
to, statements regarding our ability to become cash flow positive by the
end of 2016, future sales of our products, the ability to raise
additional capital through warrant exercises, and the Company's expected
future financial results. Forward-looking statements can be identified
with words like (and variations of): "estimate," "believe," and
"expect." These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results or
achievements to be materially different and adverse from those expressed
in or implied by the forward-looking statements. Factors that might
cause or contribute to such differences include, but are not limited to,
risks and uncertainties relating to difficulties or delays in
manufacturing, distributing, and selling the Company's products,
unexpected adverse side effects or inadequate therapeutic efficacy of
our product, the uncertainty of patent protection for the Company's
intellectual property, and the Company's ability to obtain additional
financing as necessary. Other risks relating to NovaBay's business,
including risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release, are
detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the
Securities and Exchange Commission, especially under the heading "Risk
Factors." The forward-looking statements in this release speak only as
of this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required by
law.
Stay informed on NovaBay's progress:
Download our Mobile InvestorApp from the Apple
Store or Google
Play Like us on Facebook Follow
us on Twitter Connect
with NovaBay on LinkedIn Join
us on Google+ Visit
NovaBay's
Website
View source version on businesswire.com: http://www.businesswire.com/news/home/20160613005243/en/
[ Back To Mobile World Congress's Homepage ]
|